No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
AN1 - Restructure Update
Anagenics Ltd: Annual Report to shareholders
Anagenics Ltd: FY24 4E Presentation
Anagenics Ltd: Appendix 4E and Preliminary Final Report
Anagenics Posts 16% Jump in FY 2024 Revenue, Secures Licensing Partnership
Anagenics Signs Midkine Antibody Licencing Deal With Roquefort Therapeutics